New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
Migraine is a common neurologic disorder characterized by attacks consisting of unilateral, throbbing headache accompanied by photophobia, phonophobia, and nausea which remarkably reduces the patients’ quality of life. Not migraine-specific non-steroidal anti-inflammatory drugs (NSAIDs) are effectiv...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-04-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00363/full |
| _version_ | 1819115048613707776 |
|---|---|
| author | Damiana Scuteri Annagrazia Adornetto Laura Rombolà Maria Diana Naturale Maria Diana Naturale Luigi Antonio Morrone Giacinto Bagetta Paolo Tonin Maria Tiziana Corasaniti Maria Tiziana Corasaniti |
| author_facet | Damiana Scuteri Annagrazia Adornetto Laura Rombolà Maria Diana Naturale Maria Diana Naturale Luigi Antonio Morrone Giacinto Bagetta Paolo Tonin Maria Tiziana Corasaniti Maria Tiziana Corasaniti |
| author_sort | Damiana Scuteri |
| collection | DOAJ |
| description | Migraine is a common neurologic disorder characterized by attacks consisting of unilateral, throbbing headache accompanied by photophobia, phonophobia, and nausea which remarkably reduces the patients’ quality of life. Not migraine-specific non-steroidal anti-inflammatory drugs (NSAIDs) are effective in patients affected by mild episodic migraine whilst in moderate or severe episodic migraine and in chronic migraineurs triptans and preventative therapies are needed. Since these treatments are endowed with serious side effects and have limited effectiveness new pharmacological approaches have been investigated. The demonstrated pivotal role of calcitonin gene-related peptide (CGRP) has fostered the development of CGRP antagonists, unfortunately endowed with liver toxicity, and monoclonal antibodies (mAbs) toward circulating CGRP released during migraine attack or targeting its receptor. Currently, four mAbs, eptinezumab, fremanezumab, galcanezumab for CGRP and erenumab for CGRP canonical receptor, have been studied in clinical trials for episodic and chronic migraine. Apart from the proven effectiveness, these antibodies have resulted well tolerated and could improve the compliance of the patients due to their long half-lives allowing less frequent administrations. This study aims at investigating the still poorly clear pathogenesis of migraine and the potential role of anti-CGRP mAbs in the scenario of prophylaxis of migraine. |
| first_indexed | 2024-12-22T04:55:00Z |
| format | Article |
| id | doaj.art-602c61ff55e74c35962a0bd1793b3d86 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-22T04:55:00Z |
| publishDate | 2019-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-602c61ff55e74c35962a0bd1793b3d862022-12-21T18:38:24ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-04-011010.3389/fphar.2019.00363448963New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal AntibodiesDamiana Scuteri0Annagrazia Adornetto1Laura Rombolà2Maria Diana Naturale3Maria Diana Naturale4Luigi Antonio Morrone5Giacinto Bagetta6Paolo Tonin7Maria Tiziana Corasaniti8Maria Tiziana Corasaniti9Preclinical and Translational Pharmacology, Department of Pharmacy, Health Science and Nutrition, University of Calabria, Cosenza, ItalyPreclinical and Translational Pharmacology, Department of Pharmacy, Health Science and Nutrition, University of Calabria, Cosenza, ItalyPreclinical and Translational Pharmacology, Department of Pharmacy, Health Science and Nutrition, University of Calabria, Cosenza, ItalyDepartment of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, ItalySchool of Hospital Pharmacy, University “Magna Graecia” of Catanzaro, Catanzaro, ItalyPreclinical and Translational Pharmacology, Department of Pharmacy, Health Science and Nutrition, University of Calabria, Cosenza, ItalyPreclinical and Translational Pharmacology, Department of Pharmacy, Health Science and Nutrition, University of Calabria, Cosenza, ItalyRegional Center for Serious Brain Injuries, S. Anna Institute, Crotone, ItalyDepartment of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, ItalySchool of Hospital Pharmacy, University “Magna Graecia” of Catanzaro, Catanzaro, ItalyMigraine is a common neurologic disorder characterized by attacks consisting of unilateral, throbbing headache accompanied by photophobia, phonophobia, and nausea which remarkably reduces the patients’ quality of life. Not migraine-specific non-steroidal anti-inflammatory drugs (NSAIDs) are effective in patients affected by mild episodic migraine whilst in moderate or severe episodic migraine and in chronic migraineurs triptans and preventative therapies are needed. Since these treatments are endowed with serious side effects and have limited effectiveness new pharmacological approaches have been investigated. The demonstrated pivotal role of calcitonin gene-related peptide (CGRP) has fostered the development of CGRP antagonists, unfortunately endowed with liver toxicity, and monoclonal antibodies (mAbs) toward circulating CGRP released during migraine attack or targeting its receptor. Currently, four mAbs, eptinezumab, fremanezumab, galcanezumab for CGRP and erenumab for CGRP canonical receptor, have been studied in clinical trials for episodic and chronic migraine. Apart from the proven effectiveness, these antibodies have resulted well tolerated and could improve the compliance of the patients due to their long half-lives allowing less frequent administrations. This study aims at investigating the still poorly clear pathogenesis of migraine and the potential role of anti-CGRP mAbs in the scenario of prophylaxis of migraine.https://www.frontiersin.org/article/10.3389/fphar.2019.00363/fullmigrainepharmacology of migraineCGRPtreatmentanti-CGRPmonoclonal antibodies anti-CGRP |
| spellingShingle | Damiana Scuteri Annagrazia Adornetto Laura Rombolà Maria Diana Naturale Maria Diana Naturale Luigi Antonio Morrone Giacinto Bagetta Paolo Tonin Maria Tiziana Corasaniti Maria Tiziana Corasaniti New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies Frontiers in Pharmacology migraine pharmacology of migraine CGRP treatment anti-CGRP monoclonal antibodies anti-CGRP |
| title | New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies |
| title_full | New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies |
| title_fullStr | New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies |
| title_full_unstemmed | New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies |
| title_short | New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies |
| title_sort | new trends in migraine pharmacology targeting calcitonin gene related peptide cgrp with monoclonal antibodies |
| topic | migraine pharmacology of migraine CGRP treatment anti-CGRP monoclonal antibodies anti-CGRP |
| url | https://www.frontiersin.org/article/10.3389/fphar.2019.00363/full |
| work_keys_str_mv | AT damianascuteri newtrendsinmigrainepharmacologytargetingcalcitoningenerelatedpeptidecgrpwithmonoclonalantibodies AT annagraziaadornetto newtrendsinmigrainepharmacologytargetingcalcitoningenerelatedpeptidecgrpwithmonoclonalantibodies AT laurarombola newtrendsinmigrainepharmacologytargetingcalcitoningenerelatedpeptidecgrpwithmonoclonalantibodies AT mariadiananaturale newtrendsinmigrainepharmacologytargetingcalcitoningenerelatedpeptidecgrpwithmonoclonalantibodies AT mariadiananaturale newtrendsinmigrainepharmacologytargetingcalcitoningenerelatedpeptidecgrpwithmonoclonalantibodies AT luigiantoniomorrone newtrendsinmigrainepharmacologytargetingcalcitoningenerelatedpeptidecgrpwithmonoclonalantibodies AT giacintobagetta newtrendsinmigrainepharmacologytargetingcalcitoningenerelatedpeptidecgrpwithmonoclonalantibodies AT paolotonin newtrendsinmigrainepharmacologytargetingcalcitoningenerelatedpeptidecgrpwithmonoclonalantibodies AT mariatizianacorasaniti newtrendsinmigrainepharmacologytargetingcalcitoningenerelatedpeptidecgrpwithmonoclonalantibodies AT mariatizianacorasaniti newtrendsinmigrainepharmacologytargetingcalcitoningenerelatedpeptidecgrpwithmonoclonalantibodies |